These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29721370)

  • 21. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
    Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
    J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive Immune Responses and HER2/neu Positive Breast Cancer.
    Mortenson ED; Fu YX
    Curr Pathobiol Rep; 2013 Mar; 1(1):37-42. PubMed ID: 23420038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
    Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
    Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
    J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.
    Baral R; Sherrat A; Das R; Foon KA; Bhattacharya-Chatterjee M
    Int J Cancer; 2001 Apr; 92(1):88-95. PubMed ID: 11279611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
    Dey N; Sun Y; Carlson JH; Wu H; Lin X; Leyland-Jones B; De P
    Am J Cancer Res; 2016; 6(4):714-46. PubMed ID: 27186427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.
    Jäger M; Schoberth A; Ruf P; Hess J; Lindhofer H
    Cancer Res; 2009 May; 69(10):4270-6. PubMed ID: 19435924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
    Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
    Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.
    Gibson H; Munns S; Freytag S; Barton K; Veenstra J; Bettahi I; Bissonette J; Wei WZ
    Oncoimmunology; 2015 Jan; 4(1):e984523. PubMed ID: 25949865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
    Dela Cruz JS; Lau SY; Ramirez EM; De Giovanni C; Forni G; Morrison SL; Penichet ML
    Vaccine; 2003 Mar; 21(13-14):1317-26. PubMed ID: 12615426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
    Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
    Front Immunol; 2018; 9():332. PubMed ID: 29535720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model.
    Wu J; Ma R; Cao H; Wang Z; Jing C; Sun Y; Zhang Y; Yang Z; Hoffman RM; Tang J
    Anticancer Res; 2013 Feb; 33(2):419-24. PubMed ID: 23393332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting HER2: recent developments and future directions for breast cancer patients.
    Wang SC; Zhang L; Hortobagyi GN; Hung MC
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
    Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.